Bayesian Reanalysis of Adjuvant Nivolumab in Japanese Patients With High‐Risk Muscle‐Invasive Urothelial Carcinoma
Dr. Yasuhisa Fujii is an editorial board members of International Journal of Urology and co-authors of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication.
Authors
- Hiroshi Fukushima (ORCID: https://orcid.org/0000-0001-7548-1580)
- Shugo Yajima (ORCID: https://orcid.org/0000-0003-2300-8446)
- Yosuke Yasuda (ORCID: https://orcid.org/0000-0001-5427-1680)
- Soichiro Yoshida (ORCID: https://orcid.org/0000-0003-2757-8083)
- Akihiro Hirakawa (ORCID: https://orcid.org/0000-0002-1193-8104)
- Yasuhisa Fujii (ORCID: https://orcid.org/0000-0002-6761-3229)
Institutions
- Tokyo Medical and Dental University (JP)
- National Cancer Center Hospital East (JP)
- Institute of Science Tokyo (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1111/iju.70305
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00